Chemotherapy+Pembrolizumab.

ApprovedMonoclonal antibody

Chemotherapy+Pembrolizumab. is one of 27 small molecule programs targeting Thymic Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thymic CarcinomaActive, not recruiting

Thymic CarcinomaApproved

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Thymic Carcinoma

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

—2

Beleodaq

AAcrotech Biopharma Inc.

Vepesid

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 5

Sutent

Pfizer

Phase 2

2 6

Lenvima

Eisai

Phase 2

2 7

Taxol

Teva

Phase 2

1 8

Trodelvy

Gilead

Phase 2

1 9

Afinitor

Novartis

Phase 2

1 10

Tecentriq

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thymic Carcinoma1 trial

Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

Unknown status·TTang-Du Hospital·Phase 4·NCT04554524·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chemotherapy+Pembrolizumab.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy+Pembrolizumab. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy+Pembrolizumab.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: TTang-Du Hospital

Chemotherapy+Pembrolizumab.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thymic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News